Combretastatin A-4 phosphate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Combretastatin A-4 phosphate
Combretastatin A-4 phosphate.svg
Synonyms CA4P; CA4PD; fosbretabulin; fosbretabulin disodium
PubChem CID
Chemical and physical data
Formula C18H21O8P
Molar mass 396.32 g/mol (exact mass : 396.097404)
3D model (Jmol)
For more information about this drug and its actions, see combretastatin.

Combretastatin A-4 phosphate (phosbretabulin, and its salt phosbretabulin disodium) is a microtubule destabilising drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumours causing central necrosis. It is a derivative of combretastatin.

Combretastatin A-4 phosphate (CA4P) is a prodrug. In vivo, it is dephosphorylated to its active metabolite, combretastatin A-4.[1]

CA4P is also known as Fosbretabulin Tromethamine.[2]

In July 2007 the pharmaceutical company OXiGENE initiated a 180-patient phase III clinical trial of CA-4-P in combination with carboplatin for the treatment of anaplastic thyroid cancer.[3] There is currently no fully FDA approved treatment for this form of cancer.

By 2017 it had completed multiple clinical trials (e.g. for solid tumours,[4] non-small cell lung cancer[5]) with more in progress.[6]

See also[edit]